Joana Bicker
Overview
Explore the profile of Joana Bicker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
414
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lacerda M, Carona A, Castanheira S, Falcao A, Bicker J, Fortuna A
Pharmaceutics
. 2025 Feb;
17(2).
PMID: 40006604
Cannabinoids are widely recognized for their potential therapeutic effects, making them significant and valuable candidates for medical research and applications across various fields. This review aims to analyze the pharmacokinetics...
2.
Silva R, Colom H, Almeida A, Bicker J, Carona A, Silva A, et al.
Epilepsia
. 2025 Feb;
PMID: 39932425
Objectives: Levetiracetam is a widely used antiseizure drug in patients with refractory epilepsy due to its specific mechanism of action. This study aimed to develop and validate a population pharmacokinetic...
3.
Silva R, Colom H, Almeida A, Bicker J, Carona A, Silva A, et al.
Eur J Pharm Sci
. 2025 Jan;
207:107023.
PMID: 39848412
Zonisamide exhibits significant pharmacokinetic variability, demanding for the development of population pharmacokinetic (PopPK) models to identify key factors influencing drug disposition. This study aimed to develop and validate a PopPK...
4.
Rodrigues B, Ventura E, Moreira P, Resende R, Bicker J, Santos A, et al.
Neurobiol Aging
. 2024 Dec;
147:105-123.
PMID: 39733760
Curcumin has been proposed as a potential treatment for Alzheimer's disease (AD) due to its ability to inhibit amyloid-β (Aβ) peptide aggregates and to destabilise pre-formed ones. Derivative 27 was...
5.
Gouveia F, Carona A, Lacerda M, Bicker J, Camins A, Teresa Cruz M, et al.
Biochem Pharmacol
. 2024 Nov;
230(Pt 3):116616.
PMID: 39528072
The therapeutic interest of renin-angiotensin system (RAS) drugs for the treatment of neuroinflammation has been recently acknowledged. Nevertheless, most of them display limited passage across the blood-brain barrier (BBB). Therefore,...
6.
Moreira P, Macedo J, Matos P, Bicker J, Fortuna A, Figueirinha A, et al.
Biomed Pharmacother
. 2024 Nov;
181:117652.
PMID: 39486370
Current therapies for Alzheimer's disease (AD) do not delay its progression, therefore, novel disease-modifying strategies are urgently needed. Recently, an increasing number of compounds from natural origin with protective properties...
7.
Amaral M, Romanelli M, Asiki H, Bicker J, Lage D, Freitas C, et al.
Antimicrob Agents Chemother
. 2024 Oct;
68(11):e0083124.
PMID: 39382276
Leishmaniasis is a parasitic neglected tropical disease, affecting 12 million people. Available treatments present several limitations, with an increasing number of resistance cases. In the search for new chemotherapies, the...
8.
Cordeiro A, Gomes C, Bicker J, Fortuna A
Drug Discov Today
. 2024 Jul;
29(9):104093.
PMID: 38992420
As the global population ages, the need to prolong lifespan and healthspan becomes increasingly imperative. Understanding the molecular determinants underlying cognitive resilience, together with changes during aging and the (epi)genetic...
9.
Cunha S, Bicker J, Sereno J, Falcao A, Fortuna A
Ageing Res Rev
. 2024 Jul;
99:102395.
PMID: 38950867
The blood brain barrier (BBB) is an indispensable structure that maintains the central nervous system (CNS) microenvironment for a correct neuronal function. It is composed by highly specialized microvessels, surrounded...
10.
Carona A, Bicker J, Fonseca C, da Graca Campos M, Falcao A, Fortuna A
Analyst
. 2024 Jun;
149(14):3815-3827.
PMID: 38847584
Cannabigerol, cannabidiol, cannabinol and cannabichromene are non-psychoactive phytocannabinoids, highly present in , for which numerous therapeutical applications have been described. However, additional pre-clinical and clinical data, including toxicopharmacokinetic and pharmacodynamic...